logo
Twitter
Discord
Email
logo
Viemed Healthcare, Inc.

Viemed Healthcare, Inc.

NASDAQ•VMD
CEO: Mr. Casey Hoyt
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2019-08-09
Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.
Contact Information
625 East Kaliste Saloom Road, Lafayette, LA, 70508, United States
337-504-3802
www.viemed.com
Market Cap
$283.91M
P/E (TTM)
20.8
33.6
Dividend Yield
--
52W High
$8.62
52W Low
$5.93
52W Range
52%
Rank40Top 42.0%
4.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$71.91M+23.98%
4-Quarter Trend

EPS

$0.09-9.82%
4-Quarter Trend

FCF

$10.73M+515.66%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Month Revenue Growth Revenue totaled $194.1M for nine months, marking an 18.7% increase over prior period.
Net Income Significantly Rises Net income attributable to Viemed reached $9.3M, reflecting a strong 33.8% increase.
Lehan Acquisition Closed Completed Lehan acquisition for $28.7M consideration, recognizing $25.5M in resulting goodwill.
SG&A Efficiency Gains Selling, general and administrative expenses as percentage of revenue improved to 45.9%.

Risk Factors

Gross Margin Compression Noted Gross profit margin decreased to 57.4% due to changes in the revenue mix diversification.
Regulatory Coverage Uncertainty CMS finalized NCD for NIPPV, potentially affecting patient access and reimbursement across payer base.
Cash Position Decreased Cash and cash equivalents fell to $11.1M as of September 30, 2025, from $17.5M.
Supply Chain Cost Pressures Ongoing cost pressures from material, labor, and potential tariff escalation create operational uncertainty.

Outlook

Future Growth Strategy Expect growth through expansion of existing service areas and efficient launch into new territories.
Debt Repayment Anticipated Anticipate reduction in quarterly net interest expense for remainder of 2025 due to expected debt repayments.
Share Repurchase Completed Completed the 2025 Share Repurchase Program during the quarter, canceling 1.7M shares.
SG&A Improvement Expected Expect SG&A as percentage of revenue to continue improving through end of 2025 via efficiency initiatives.

Peer Comparison

Revenue (TTM)

Inogen, Inc.INGN
$347.03M
+4.7%
Tactile Systems Technology, Inc.TCMD
$311.51M
+9.3%
Viemed Healthcare, Inc.VMD
$254.79M
+18.1%

Gross Margin (Latest Quarter)

CVRx, Inc.CVRX
86.8%
+3.6pp
Tactile Systems Technology, Inc.TCMD
75.8%
+1.7pp
BrainsWay Ltd.BWAY
75.2%
+1.7pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TCMD$647.29M36.48.8%6.5%
NRC$477.39M29.167.8%59.0%
BWAY$458.11M74.39.5%6.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.8%
Steady Growth
4Q Net Income CAGR
-6.6%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Mar 9, 2026
|
EPS:$0.12
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $71.91M+24.0%
    |
    EPS: $0.09-9.8%
    Meet
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $63.06M+14.7%
    |
    EPS: $0.08+111.4%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 7, 2025|
    Revenue: $59.13M+16.9%
    |
    EPS: $0.07+75.0%
    Beat
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 10, 2025|
    Revenue: $224.26M+22.5%
    |
    EPS: $0.29+7.4%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $58.00M+17.4%
    |
    EPS: $0.10+33.1%
    Beat
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 7, 2024|
    Revenue: $54.97M+26.9%
    |
    EPS: $0.04-38.6%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 6, 2024|
    Revenue: $50.59M+27.9%
    |
    EPS: $0.04+0.5%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 6, 2024|
    Revenue: $183.01M+31.8%
    |
    EPS: $0.27+80.0%
    Beat